2011/11/22 10:08 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in patients with Type 2 Diabetes. Based on the positive outcome of the FDA meeting held on November 18, Mesoblast will file an Investigational New Drug (IND) submission within the next 30-60 days to seek clearance for patient recruitment.
2011/11/15 08:25 - Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor(TM) after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results in 60 patients were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston.
2011/11/10 08:27 - Regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona.
2011/11/01 12:00 - Asian Activities Report for November 1, 2011 includes: Montezuma Mining Company Ltd (ASX:MZM) reports outstanding copper results from a recently completed 19-hole drilling programme at the Company's 100% owned Butcherbird Copper Project in Western Australia; Hannans Reward Ltd (ASX:HNR) provides an update on its drilling program currently underway at the Jigalong Project; Biomedical company, Tissue Therapies Limited (ASX:TIS) says today that the VitroGro(R) synthetic protein has been classified as a biologic product by the US Food and Drug Administration; Navigator Resources Limited (ASX:NAV) has achieved the production milestone of 100,000 ounces of gold poured since it commenced operation at the Company's Bronzewing Gold Project, located 960km northeast of Perth.
2011/10/31 10:36 - Agenix Limited (ASX:AGX) is pleased to provide Chairman's Address to shareholders at 2011 Annual General Meeting.
2011/10/27 12:00 - Asian Activities Report for October 27, 2011 includes: C @ Limited (ASX:CEO) has signed an agreement to acquire eight highly prospective Mongolian coal licences for US$7.8 millions; African Iron Limited (ASX:AKI) announces a 267% increase in the JORC hematite mineral resource to 121 million tonnes at its 92% owned Mayoko Iron Ore Project in Congo; ENK Plc (ASX:ENK) announces the first nickel production from its pilot plant located 250 km north of Manila in the Philippines; Solagran Limited (ASX:SLA) recently visited an Asian country where a poultry trial was conducted in collaboration with a government body in the field of poultry production and disease management.
2011/10/24 09:48 - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes - neovascular ("wet") Age-related Macular Degeneration (AMD). Wet AMD causes sudden and severe central vision loss and accounts for approximately 90 percent of all blindness in the elderly. Mesoblast is developing a stem cell therapeutic product for treating various vascular diseases of the eye, including wet AMD and diabetic macular edema (DME).
2011/10/20 10:21 - Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.
2011/10/18 13:03 - Asian Activities Report for October 18, 2011 includes: Algae. Tec Limited (ASX:AEB) has received regulatory approvals for the development of an algae demonstration plant in the south of Sydney; Helicon Group Limited (ASX:HCG) today announces the execution of a definitive agreement to acquire Aspen Medisys; Alkane Resources Limited (ASX:ALK) has signed an agreement with the NSW Government to receive financial assistance for the infrastructure development of the Tomingley Gold Project in the Central West of NSW; Transerv Energy Limited (ASX:TSV) has completed the initial 10-day test of the Upper Zone at the Warro-4 onshore well in Western Australia; Augur Resources Limited (ASX:AUK) reports extensive gold and copper results from the Randu Kuning prospect, Wonogiri project in Central Java.
2011/10/17 12:00 - Asian Activities Report for October 17, 2011 includes: International Coal Limited (ASX:ICX) has expanded the drilling programme at its wholly owned South Blackall Project in Queensland; Avanco Resources Limited (ASX:AVB) reported excellent results from the Rio Verde Copper Project in Brazil; Cardia Bioplastics Limited (ASX:CNN) has received BioNexus Status in Malaysia; Mantle Mining Corporation Limited (ASX:MNM) has completed the first 4 holes of a 15 hole drill program at the Company's 100% owned Bacchus Marsh coal project in Victoria; Vocus Communications (ASX:VOC), a Seven Group Holdings (ASX:SVW) company, has secured a multi-year deal to provide IP Transit and Data Centre services to leading 4G wireless provider vividwireless.
2011/10/13 08:26 - Agenix Limited (ASX:AGX) today confirmed it had signed two new agreements with its strategic partners in China covering the commercialisation of new drug candidates, the sharing of resources, expertise and completion of pre-clinical toxicology tests for its new hepatitis B drug in China.
2011/10/11 12:00 - Asian Activities Report for October 11, 2011 includes: Allied Healthcare Group (ASX:AHZ) says today that its investee company Coridon Pty Ltd has successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 vaccine with outstanding results; Universal Biosensors, Inc. (ASX:UBI) has commenced a new research and development project for Cilag GmbH International to determine the feasibility of an innovative blood glucose product to be used in the field of diabetes; Kalgoorlie Mining Company Limited (ASX:KMC) reports that recent drilling of the East Lode at the Bullant gold mine has intersected a spectacular high grade gold zone; Midas Resources Limited (ASX:MDS) will commence aircore drilling on a gold target south of the Intrepid Prospect at the Company's Lake Carey Project in Western Australia.
2011/10/10 12:00 - Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.
2011/10/07 16:01 - China's medical industry and government working together towards a brighter and technologically advanced future at the 3rd China International Medical Device Summit in Beijing.
2011/09/30 14:32 - Agenix Limited (ASX:AGX) confirmed its promising new hepatitis B drug, AGX-1009, shared the same active compound as Gilead's blockbuster drug, Viread, which is widely used to treat HIV and hepatitis throughout Asia.
2011/09/30 12:00 - Asian Activities Report for September 30, 2011 includes: Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream; India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine; Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt; Tissue Therapies Limited (ASX:TIS) will start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012; Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225; Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100.
2011/09/29 12:00 - Asian Activities Report for September 29, 2011 includes: Red Mountain Mining Limited (ASX:RMX) will commence a Stage II underground drilling program on 29 September 2011 at the Zhongqu project in Gansu Province, China; Atlantic Limited (ASX:ATI) has signed an agreement to undertake a development study of Vietnam's bauxite extraction and supply chain industry, particularly in the Central Highlands of the country; Rico Resources Limited (ASX:RRI) has commenced a major resource definition drilling programme at the Wonmunna Project in the East Pilbara iron ore mining region; Rift Valley Resources Limited (ASX:RFV) today announced the acquisition of two new gold projects in the Lake Victoria Goldfields region of Tanzania; Novogen Limited (ASX:NRT) (NASDAQ:NVGN) will invest US$2 million in Marshall Edwards (NASDAQ:MSHL) to support ongoing medical research; Pipavav Defence and Offshore Engineering Company Limited (BOM:533107) and Airbus will develop state-of-the-art Maintenance, Repair and Overhaul facilities and associated infrastructure in India.
2011/09/28 12:02 - Asian Activities Report for September 28, 2011 includes: Fletcher Building Limited (ASX:FBU) said today that Iplex Pipelines has been awarded a A$120 million contract for the supply of polyethylene pipe; Integra Mining Limited (ASX:IGR) reported aircore drilling results from reconnaissance drilling in the Mt Monger area; African Iron Limited (ASX:AKI) provides an update on drilling activities at its 92%-owned Mayoko iron ore project in the Republic of Congo; Alchemia Limited (ASX:ACL) said today that its leading cancer product HA-Irinotecan has received very promising trial results; Tata Communications (BOM:500483) has become one of the few global carriers to extend its Global IP/VPN service offerings into Pakistan.
2011/09/27 12:00 - Asian Activities Report for September 27, 2011 includes: General Mining Corporation Limited (ASX:GMM) has signed an agreement to acquire a coal exploration licence in Mongolia; Aphrodite Gold Limited (ASX:AQQ) announced further robust gold intersections at its Aphrodite Gold Deposit; Agenix Limited (ASX:AGX) has filed a patent application for its hepatitis B drug AGX-1009; Manas Resources Limited (ASX:MSR) reported a 20% increase in its Shambesai Total Mineral Resource to 766,000 ounces of gold; Infotech Enterprises Limited (BOM:532175) announced its partnership with Software Engineering Institute.
2011/09/27 08:27 - Global regenerative medicine company Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN), a world leader in biologic manufacturing, today announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast's off-the-shelf (allogeneic) adult stem cell products.
2011/09/09 14:16 - ADX Energy Ltd (ASX:ADX) is pleased to announce a Sale and Purchase Agreement has been executed to buy back a further 10% interest in the Lambouka Prospect Area in the Kerkouane Permit from PharmAust Limited (ASX:PAA) and to cancel the option of PAA to purchase an interest in that part of the Lambouka prospect that extends into Italian waters.
2011/09/09 12:00 - Asian Activities Report for September 9, 2011 includes: HealthLinx Limited (ASX:HTX) is to begin a 350 patient academic study as the first step to launch the OvPlex(TM) ovarian cancer diagnostic in China; Amex Resources Limited (ASX:AXZ) today provided an update on the Company's recent advancements on the MBa Delta Ironsands Project in Fiji; Orocobre Limited (ASX:ORE) has received approval to drill exploratory wells on its Cauchari Project in Argentina; Coalbank Limited (ASX:CBQ) has engaged an independent technical expert to review its metals projects portfolio.
2011/09/07 12:02 - Asian Activities Report for September 7, 2011 includes: AnaeCo Limited (ASX:ANQ) has formed a joint venture company for the deployment of the DiCOM(TM) System in Asia; Integra Mining Limited (ASX:IGR) says today that the first month of production following the Randalls Gold Project processing facility upgrade has exceeded expectations; Krucible Metals Limited (ASX:KRB) has received drilling results at the Korella Phosphate and Rare Earth Project in Queensland; ZYL Limited (ASX:ZYL) announced the interim results of the Bankable Feasibility Study at the Kangwane Anthracite Project; Suven Life Sciences Limited (BOM:530239) announces the grant of four product patents from Australia and New Zealand.
2011/09/05 08:36 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks.
2011/09/01 12:00 - Asian Activities Report for September 1, 2011 includes: CBD Energy (ASX:CBD) has signed an agreement to participate in the management of the AusChina Energy Joint Venture; TVN Corporation Pty Ltd (ASX:TVN) announced the results from its latest drilling on the Nuurst Project in Mongolia; Uran Limited (ASX:URA) has commenced commercial open pit mining activities at the Emmanuel Project in Zambia; Aviva Corporation Limited (ASX:AVA) has recently completed a maiden resource estimate on the Bumbo Base Metal Deposit in West Kenya; Manas Resources Limited (ASX:MSR) has completed a 12,500 metre drilling program at Shambesai Gold Project in the Kyrgyz Republic; Daiichi Sankyo Company, Limited (TYO:4568) and Ranbaxy Laboratories Limited (BOM:500359) today announced a joint initiative to sponsor mobile healthcare clinics in India, Cameroon and Tanzania.
2011/08/24 12:00 - Asian Activities Report for August 24, 2011 includes: TVN Corporation Pty Ltd (ASX:TVN) announced the results from its latest drilling activities at the Nuurst Project in Mongolia; PMI Gold Corporation (ASX:PVM) reported further positive drilling results from its 100%-owned Obotan Gold Project in Ghana; Senex Energy Limited (ASX:SXY) secures agreement for the pipeline transportation of crude oil from Snatcher oil field; Australia Minerals and Mining Group Limited (ASX:AKA) has updated its kaolin resource at Yilgarn project areas in Western Australia; Biocon Limited's (BOM:532523) subsidiary Clinigene International Limited has signed a strategic partnership agreement with Spaulding Clinical Research, LLC.
2011/08/24 10:00 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million.
2011/08/22 08:32 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the first minimally-invasive lumbar disc procedure had been successfully performed in the Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell product for the treatment of low back pain and degenerative disc disease. The outpatient procedure lasted less than 20 minutes, with the patient fully awake and under light sedation. The patient was shortly discharged and there were no complications.
2011/08/19 12:00 - Asian Activities Report for August 19, 2011 includes: SmartTrans Holdings Limited (ASX:SMA) has signed a binding agreement with China Mobile (HKG:0941) (NYSE:CHL) that allows SmartTrans to collect payment from China Mobile customers; Golden Rim Resources Limited (ASX:GMR) today announced copper and gold intersections from the second program of reverse circulation drilling at its Balogo Project in Burkina Faso; Highlands Pacific Limited (ASX:HIG) said today that its fully constructed US$1.5 billion Ramu Nickel project in Papua New Guinea will commence ore commissioning activities at the Basamuk treatment plant in September; Aquila Resources Limited (ASX:AQA) said today that the Queensland Government has granted the Mining Lease for the Eagle Downs Hard Coking Coal Project in Central Queensland; Suven Life Sciences Limited (BOM:530239) has been granted 4 product patents for the treatment of Neurodegenerative disorders.
2011/08/15 09:40 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.
2011/08/12 12:00 - Asian Activities Report for August 12, 2011 includes: Newly ASX-listed rare earths company Strategic Elements Limited (ASX:SOR) has expanded its search for rare earths and rare metals to Ireland; Dragon Mining Limited (ASX:DRA) has received the first results from the drilling campaign on the Hangaslampi gold deposit in northern Finland; Canyon Resources Limited (ASX:CAY) has entered into an agreement to purchase the Wilier Project in eastern Burkina Faso; Whinnen Resources Limited (ASX:WWW) has commenced its maiden drilling program at the Nany-Varas gold project in Northern Chile; Piramal Healthcare (BOM:500302) and Vodafone Group (LON:VOD) announced that Piramal has agreed to purchase approximately 5.5% of the issued equity share capital of Vodafone Essar Limited.
2011/08/02 12:00 - Asian Activities Report for August 2, 2011 includes: Astro Resources NL (ASX:ARO) has secured the rights to acquire the majority share in the Scott Coastal Plain Mineral Sands Project in Western Australia; Nexbis Limited (ASX:NBS) has signed a 12-year agreement for its Malaysian project; Gullewa Limited (ASX:GUL) reported a three-metre thick coal seam at Back Creek in Queensland; China Magnesium Corporation Limited's (ASX:CMC) first phase expansion of the Pingyao Magnesium Project is progressing as expected and on schedule; Claris Lifesciences Limited (BOM:533288) received approvals to re-launch its Bag Products in the European Union.
2011/07/29 12:00 - Asian Activities Report for July 29, 2011 includes: Northern Minerals Limited (ASX:NTU) announced exciting Heavy Rare Earth Element results from the Browns Range Project in northern Western Australia; Scandinavian Resources Limited (ASX:SCR) has updated global JORC compliant mineral resource for the Kiruna Iron Project in northern Sweden; Venture Minerals Limited (ASX:VMS) announced a maiden direct shipping ore resource of 2.2 million tonnes at 58% Fe at the newly defined Livingstone Deposit; Australia China Holdings Limited (ASX:AAK) has signed a Memorandum of Understanding with Denzo Group to form a Joint Venture Company in China; Dr. Reddy's Laboratories Limited (BOM:500124) has signed a Memorandum of Understanding with Fujifilm Corporation (TYO:4901) for an exclusive partnership in the Generic Drugs business for the Japanese market.
2011/07/28 12:02 - Asian Activities Report for July 28, 2011 includes: Novogen Limited's (ASX:NRT) subsidiary, Marshall Edwards, Inc.(NASDAQ:MSHL) announced the publication of results from a pre-clinical study of NV-128; Anatolia Energy Limited (ASX:AEK) announced an initial JORC Mineral Resource estimate for the Temrezli uranium prospect in Turkey; Waratah Resources Limited (ASX:WGO) has signed a binding Share Sale Agreement to acquire the Okanabora Project in the Republic of Congo; David Jones Limited (ASX:DJS) is launching a new brand campaign for Spring/Summer 2011.
2011/07/07 09:23 - Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission.
2011/06/29 09:22 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell (MPC) product for the treatment of degenerative disc disease.
2011/06/14 12:26 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum.
2011/06/09 09:39 - Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.
2011/06/08 12:00 - Asian Activities Report for June 8, 2011 includes: Agenix (ASX:AGX) is on track to begin clinical trials in China for its lead Hepatitis B drug; Central Asia Resources Limited (ASX:CVR) reported gold resource increase to 124,000 ounces at Dalabai Gold Project; Tanami Gold NL (ASX:TAM) announced a further substantial increase in its gold Mineral Resources to 2.30 million ounces of gold; Corazon Mining Limited (ASX:CZN) confirmed the existence of a high-grade nickel/copper sulphide discovery at the Lynn Lake nickel sulphide project in Canada.
2011/06/06 10:19 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum.